Preferred Label : Supra-pharmacologic Dexamethasone Sodium Phosphate AVM0703;
NCIt synonyms : AugmenStem (TM); PlenaStem (TM);
NCIt definition : A supra-pharmacologic, high-volume formulation containing the sodium phosphate form
of the corticosteroid dexamethasone, with potential antineoplastic and lymphoablative,
and with anti-inflammatory and immunomodulating activities. Upon administration of
supra-pharmacologic dexamethasone sodium phosphate AVM0703, dexamethasone targets
and binds to the cytoplasmic glucocorticoid receptor (GR); then the receptor-ligand
complex is translocated to the nucleus where it initiates the transcription of genes
encoding for anti-inflammatory mediators, such as cytokines and lipocortins. More
importantly, AVM0703 is able to supercharge and mobilize various lymphocytes and monocytes,
such as natural killer T-cells (NK/T), gamma delta T-cells and dendritic cells (DCs).
These immune cells, in turn, invade and destroy certain tumor cells. In addition,
these immune cells that are induced by AVM0703 may also be able to kill viruses, such
as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By depleting monocytes,
AVM0703 may also reduce cytokine-release syndrome (CRS). AVM0703 also lympho-ablates
both T and B lymphocytes for 'immune reset' via receptor mediated induction of caspase
dependent apoptosis. This specific dexamethasone formulation contains about twenty-five
times the dose of other dexamethasone formulations. AVM0703 does not have an effect
on red blood cells (RBCs), platelets, and hematopoietic stem cells (HSCs).;
Molecule name : AVM 0703; AVM-0703;
NCI Metathesaurus CUI : CL1406759;
Origin ID : C172928;
UMLS CUI : C5417950;
Semantic type(s)
- chemical_or_drug_is_metabolized_by_enzyme
- concept_is_in_subset
- has_target
